134 related articles for article (PubMed ID: 2192300)
1. Met-enkephalin immunoreactivity in the basal ganglia in Parkinson's disease and striatonigral degeneration.
Goto S; Hirano A; Matsumoto S
Neurology; 1990 Jul; 40(7):1051-6. PubMed ID: 2192300
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical visualization of afferent nerve terminals in human globus pallidus and its alteration in neostriatal neurodegenerative disorders.
Goto S; Hirano A; Rojas-Corona RR
Acta Neuropathol; 1989; 78(5):543-50. PubMed ID: 2479214
[TBL] [Abstract][Full Text] [Related]
3. Striosomal organization of substance P-like immunoreactivity in parkinsonian patients.
Sakamoto S; Goto S; Ito H; Hirano A
Neurology; 1992 May; 42(5):1071-5. PubMed ID: 1374545
[TBL] [Abstract][Full Text] [Related]
4. Immunocytochemical studies of substance P and leucine-enkephalin in Huntington's disease.
Marshall PE; Landis DM; Zalneraitis EL
Brain Res; 1983 Dec; 289(1-2):11-26. PubMed ID: 6198034
[TBL] [Abstract][Full Text] [Related]
5. A comparative immunohistochemical study on striatal Met-enkephalin expression in Alzheimer's disease and in progressive supranuclear palsy.
Matsumoto S; Goto S; Hirano A
Acta Neuropathol; 1990; 81(1):74-7. PubMed ID: 2085095
[TBL] [Abstract][Full Text] [Related]
6. Striatal opioid receptor binding in Parkinson's disease, striatonigral degeneration and Steele-Richardson-Olszewski syndrome, A [11C]diprenorphine PET study.
Burn DJ; Rinne JO; Quinn NP; Lees AJ; Marsden CD; Brooks DJ
Brain; 1995 Aug; 118 ( Pt 4)():951-8. PubMed ID: 7655890
[TBL] [Abstract][Full Text] [Related]
7. Contrasting responses by basal ganglia met-enkephalin systems to low and high doses of methamphetamine in a rat model.
Alburges ME; Keefe KA; Hanson GR
J Neurochem; 2001 Feb; 76(3):721-9. PubMed ID: 11158242
[TBL] [Abstract][Full Text] [Related]
8. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
Brooks DJ; Ibanez V; Sawle GV; Playford ED; Quinn N; Mathias CJ; Lees AJ; Marsden CD; Bannister R; Frackowiak RS
Ann Neurol; 1992 Feb; 31(2):184-92. PubMed ID: 1575457
[TBL] [Abstract][Full Text] [Related]
9. Immunocytochemical studies of substance P and Met-enkephalin in the basal ganglia and substantia nigra in Huntington's, Parkinson's and Alzheimer's diseases.
Grafe MR; Forno LS; Eng LF
J Neuropathol Exp Neurol; 1985 Jan; 44(1):47-59. PubMed ID: 2578185
[TBL] [Abstract][Full Text] [Related]
10. Neuropeptides in the basal ganglia.
Graybiel AM
Res Publ Assoc Res Nerv Ment Dis; 1986; 64():135-61. PubMed ID: 2425403
[No Abstract] [Full Text] [Related]
11. Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea.
Waters CM; Peck R; Rossor M; Reynolds GP; Hunt SP
Neuroscience; 1988 May; 25(2):419-38. PubMed ID: 2456487
[TBL] [Abstract][Full Text] [Related]
12. Topographic involvement of the striatal efferents in basal ganglia of patients with adult-onset motor neuron disease with basophilic inclusions.
Ito H; Kusaka H; Matsumoto S; Imai T
Acta Neuropathol; 1995; 89(6):513-8. PubMed ID: 7545858
[TBL] [Abstract][Full Text] [Related]
13. Inhomogeneity of the putaminal lesion in striatonigral degeneration.
Goto S; Hirano A
Acta Neuropathol; 1990; 80(2):204-7. PubMed ID: 1975151
[TBL] [Abstract][Full Text] [Related]
14. Increased basal ganglia iron in striatonigral degeneration: in vivo estimation with magnetic resonance.
Martin WR; Roberts TE; Ye FQ; Allen PS
Can J Neurol Sci; 1998 Feb; 25(1):44-7. PubMed ID: 9532280
[TBL] [Abstract][Full Text] [Related]
15. Decreased pallidal vesicular monoamine transporter type 2 availability in Parkinson's disease: The contribution of the nigropallidal pathway.
Cho SS; Christopher L; Koshimori Y; Li C; Lang AE; Houle S; Strafella AP
Neurobiol Dis; 2019 Apr; 124():176-182. PubMed ID: 30471418
[TBL] [Abstract][Full Text] [Related]
16. Striosomal arrangement of met-enkephalin and substance P expression in parkinsonism-dementia complex on Guam.
Ito H; Goto S; Sakamoto S; Hirano A
Acta Neuropathol; 1993; 85(4):390-3. PubMed ID: 7683167
[TBL] [Abstract][Full Text] [Related]
17. Calbindin-D28k in the basal ganglia of patients with parkinsonism.
Ito H; Goto S; Sakamoto S; Hirano A
Ann Neurol; 1992 Oct; 32(4):543-50. PubMed ID: 1456738
[TBL] [Abstract][Full Text] [Related]
18. Loss of substance P and enkephalin immunoreactivity in the human substantia nigra after striato-pallidal infarction.
Pioro EP; Hughes JT; Cuello AC
Brain Res; 1984 Feb; 292(2):339-47. PubMed ID: 6198046
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical demonstration of differential substance P-, met-enkephalin-, and glutamic-acid-decarboxylase-containing cell body and axon distributions in the corpus striatum of the cat.
Beckstead RM; Kersey KS
J Comp Neurol; 1985 Feb; 232(4):481-98. PubMed ID: 2579980
[TBL] [Abstract][Full Text] [Related]
20. Calcineurin immunoreactivity in striatonigral degeneration.
Goto S; Hirano A; Rojas-Corona RR
Acta Neuropathol; 1989; 78(1):65-71. PubMed ID: 2544073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
